Late-Stage Breast Cancer Diagnosis on Rise in U.S.
SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...
Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...
Madison WMTV on MSN1d
Oregon school teacher and metastatic breast cancer advocate being remembered by her familyMary Gooze, a beloved teacher, cancer advocate, and swimmer passed away last month after a 13-year battle with stage IV ...
Medpage Today on MSN9h
HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast CancerA HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...
Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...
Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment ...
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated ...
This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast ...
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...
Breast cancer caregiving was the last thing on John K. Conner’s mind back in 1998. He and his wife, Anita T. Conner, were in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback